BRIEF-Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
BRIEF-Alpha Cognition Inc - On Track And Plans To Release Data From Alpha-1062 Pivotal Trial During Q2 Of 2022
May 31 (Reuters) - Alpha Cognition Inc ACOG.V :
5 月 31 日（路透社）— Alpha Cognition Inc ACOG.V：
* ALPHA COGNITION INC - ON TRACK AND PLANS TO RELEASE DATA FROM ALPHA-1062 PIVOTAL TRIAL DURING Q2 OF 2022
* ALPHA COGNITION INC-步入正軌，計劃在2022年第二季度發佈來自ALPHA-1062關鍵試驗的數據
* ALPHA COGNITION INC - PLANS TO MEET WITH FDA FOR ALPHA-1062 INTRANASAL FOR MTBI DURING Q3 OF 2022
* ALPHA COGNITION INC-計劃在2022年第三季度與美國食品藥品管理局會面，討論MTBI的ALPHA-1062鼻內注射
* ALPHA COGNITION INC - Q1 2022 NET LOSS WAS $2.7 MILLION, OR A NET LOSS OF $0.04 PER SHARE
* ALPHA COGNITION INC-2022 年第一季度淨虧損爲 270 萬美元，合每股淨虧損 0.04 美元
* ALPHA COGNITION INC - CASH, CASH EQUIVALENTS AS OF MARCH 31, 2022, WERE $9.1 MILLION
* ALPHA COGNITION INC——截至2022年3月31日，現金、現金等價物爲910萬美元
Source text for Eikon: ID:nBw2kCFj7a Further company coverage: ACOG.V
Eikon 的來源文本：id: nbw2kcfj7A 進一步的公司報道：ACOG.V
譯文內容由第三人軟體翻譯。